Erdafitinib Patent Expiration
Erdafitinib is Used for treating locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations that has progressed after prior systemic therapy. It was first introduced by Janssen Biotech Inc
Erdafitinib Patents
Given below is the list of patents protecting Erdafitinib, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Balversa | US11077106 | Cancer treatment | Feb 02, 2038 | Janssen Biotech |
| Balversa | US10478494 | FGFR/PD-1 combination therapy for the treatment of cancer | Aug 13, 2036 | Janssen Biotech |
| Balversa | US12678498 | Fgfr/Pd-1 Combination Therapy For The Treatment Of Cancer | Jun 13, 2036 | Janssen Biotech |
| Balversa | US10898482 | Pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N'-1 methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine | Feb 09, 2036 | Janssen Biotech |
| Balversa | US11684620 | Pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N′-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine | Feb 09, 2036 | Janssen Biotech |
| Balversa | US12037644 | Use of FGFR mutant gene panels in identifying cancer patients that will be responsive to treatment with an FGFR inhibitor | Oct 18, 2035 | Janssen Biotech |
| Balversa | US9902714 | Quinoxaline derivatives useful as FGFR kinase modulators | Mar 26, 2035 | Janssen Biotech |
| Balversa | US8895601 | Pyrazolyl quinoxaline kinase inhibitors | Apr 12, 2033 | Janssen Biotech |
| Balversa | US9464071 | Pyrazolyl quinoxaline kinase inhibitors | Apr 28, 2031 | Janssen Biotech |
Erdafitinib's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Erdafitinib:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
